Advances in Follicular-Lymphoma

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 66-71

  Archuleta, Travis D ^a   Armitage, James O ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; INTERFERON; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; FEVER; FOLLICULAR LYMPHOMA; HUMAN; MALAISE; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION;

EID: 2342660723     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.007     Document Type: Conference Paper

References (46)

1. Armitage JO, Weisenberger DD: New approach to classifying non-Hodgkin's lymphoma: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998
2. Hoffman R, et al: Hematology: Basic Principles and Practice (3rd ed). Philadelphia, PA, Churchill Livingstone, 2000
3. Rodriguez J, McLaughlin P, Hagemeister FB, et al: Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic factors. Blood 93: 2202-2207, 1999
4. Hans CP, Weisenburger DD, Vose JM, et al: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003
5. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
6. Wilder RB, Jones D, Tucker SL, et al: Long term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001
7. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
8. Gospodarowicz MK: Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 10:489-497, 1984
9. Seymour JF, Pro B, Fuller LM, et al: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003
10. Homing SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
11. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphomas. J Clin Oncol 12:1343-1348, 1994
12. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advance follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
13. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
14. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
15. Zinzani PL, Bendandi M, Tura S, et al: FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Hematol 55:262-266, 1995
16. Hochster HS, Oken MM, Winter JH, et al: Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up-A report from the Eastern Cooperative Oncology Group. J Clin Oncol 18:987-994, 2000
17. Keating MJ, McLaughlin P, Cabanillas F, et al: Low-grade non-Hodgkin's lymphoma-Development of a new effective combination regimen (fludarabine, mitoxantrone, and dexamethasone: FND). Eur J Cancer Care 6:21-22, 1997 (suppl 4)
18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
19. Hainsworth JD, Burris HA III, Morrissey LH, et al: Rituximab monoclonal antibody therapy as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 95:3052-3056, 2000
20. Hainsworth JD, Litchy J, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
21. Yossi C, Solal-Celigny P, Polliack A, et al: Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapse disease, re-treatment and maintenance. Trends Hematol Oncol 88:811-823, 2003
22. Ghielmini M, Hsu Schmitz SF, Cogliatti SB, et al: Maintenance treatment with 2-monthly rituximab after standard weekly x 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 13:112a, 2002 (abstr)
23. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003
24. Khorana A, Bunn M, McLaughlin P, et al: A phase II multicenter study of Campath-lH antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 41:77-87, 2001
25. Vose J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma-III. Immunotherapy for non-Hodgkin's lymphoma. In: Broudy VS, Abkowitz JL, Vose JM (eds): Hematology 2002: American Society of Hematology Education Program Book. Washington, DC, 2002, pp 250-257
26. Kaminski MS, Estes J, Tuck M, et al: Iodine 131 tositumomab therapy for previously untreated follicular lymphoma. Proc Am Soc Clin Oncol 19:11a, 2000 (abstr)
27. Davis TA, Kaminiski MS, Leonard JP, et al: Results of a randomized study of Bexxar vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL). Blood 98-3503a, 2001 (abstr)
28. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine-131 (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma. J Clin Oncol 19:3918-3928, 2001
29. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine 131 tositumomab for chemotherapy refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 18:1316-1323, 2000
30. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3268, 2002
31. Witzig TE, Gordon LI, Cabanillas F, et al: Prospective controlled randomized trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
32. Smalley RV, Weller E, Hawkins MJ, et al: Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen. Leukemia 15:118-1122, 2001
33. Neri N, Aviles A, Cleto S, et al: Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. J Hematother Stem Cell Res 10:669-674, 2001
34. Arranz R, Garcia-Alfonso P, Sobrino P, et al: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multi-center trial with double randomization. J Clin Oncol 16:1538-1546, 1998
35. Solal-Celigny P, Lepage F, Brousse N, et al: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculares 86 trial. J Clin Oncol 16:2332-2338, 1998
36. Allen I, Ross SD, Borden SP, et al: Meta-analysis to assess the efficacy of interferon-alfa in patients with follicular lymphoma. J Immunother 24:58-65, 2001
37. Homing SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001
38. Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
39. Colambat P, Comillet P, Deconinck E, et al: Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study. Bone Marrow Transplant 26:971-977, 2000
40. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997
41. Richardson P: Clinical update: proteosome inhibitors in hematologic malignancies. Cancer Treat Rev 29:33-39, 2003 (suppl 1)
42. O'Connor OA, Wright J, Moskowitz B, et al: Phase II clinical experience with the proteozome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 22:566, 2003 abstr 2277
43. Lee MS: Molecular aspects of chromosomal translocation t(14;18). Semin Hematol 27:879-884, 1993
44. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes (comment). Cell 79:189-192, 1994
45. Waters JS, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823, 2000
46. Webb A, Cunningham D, Cotter F, et al: Bcl-2 anti-sense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141, 1997